Amarin Corporation plc - American Depositary Shares (NQ:AMRN)

14.22 -0.25 (-1.73%)

Streaming Delayed Price Updated: 2:53 PM EDT, Jun 3, 2026 Add to My Watchlist

Price and Volume

Volume	35,882
Open	14.47
Bid (Size)	14.22 (100)
Ask (Size)	14.39 (400)
Prev. Close	14.47
Today's Range	14.20 - 14.78
52wk Range	11.42 - 20.90
Shares Outstanding	407,265,944
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

New REDUCE-IT® Analysis Presented at the European Atherosclerosis Society (EAS) Congress 2026 Suggests Risk-Weighted ApoB May Improve Identification of Residual Cardiovascular Risk in Statin-Treated Patients with Hypertriglyceridemia

May 27, 2026

From Amarin Corporation plc

Via GlobeNewswire

Amarin (AMRN) Q1 2026 Earnings Transcript ↗

April 30, 2026

Amarin (AMRN) Q1 2026 Earnings Transcript

Via The Motley Fool

Performance

YTD	+3.6%	+3.6%
1 Month	-0.1%	-0.1%
3 Month	-0.9%	-0.9%
6 Month	-8.4%	-8.4%
1 Year	+21.1%	+21.1%

More News

Amarin (NASDAQ:AMRN) Surprises with Revenue Beat but EPS Falls Short Amid Restructuring Costs ↗

April 29, 2026

Via Chartmill

Amarin Reports 2026 First Quarter Financial Results

April 29, 2026

From Amarin Corporation plc

Via GlobeNewswire

Amarin Corp (NASDAQ:AMRN) Narrows Losses and Beats Adjusted EPS in Q4 2025 ↗

February 25, 2026

Via Chartmill

Earnings Scheduled For October 29, 2025 ↗

October 29, 2025

Via Benzinga

Amarin (AMRN) Q2 2025 Earnings Transcript ↗

April 21, 2026

Via The Motley Fool

Amarin (AMRN) Q3 2025 Earnings Transcript ↗

April 21, 2026

Via The Motley Fool

Amarin to Report First Quarter 2026 Financial Results and Host Conference Call on April 29, 2026

April 15, 2026

From Amarin Corporation plc

Via GlobeNewswire

Biohaven Stock Down 70% but One Fund's New $6 Million Bet Signals Turnaround Potential ↗

March 23, 2026

Via The Motley Fool

Amarin Highlights Guideline Recommended Role of Icosapent Ethyl in Managing Cardiovascular Risk Following Release of Updated 2026 ACC/AHA/Multisociety Dyslipidemia Guideline

March 18, 2026

From Amarin Corporation plc

Via GlobeNewswire

New REDUCE-IT Data in Patients at Extreme Cardiovascular Risk and In Vitro Research on the Mechanistic Effects of Eicosapentaenoic Acid (EPA) on Lipoprotein(a) [Lp(a)] Oxidation to be Presented at the American College of Cardiology’s (ACC) Annual

March 16, 2026

From Amarin Corporation plc

Via GlobeNewswire

Here's Why I Wouldn't Touch Amarin With a 10‑Foot Pole Given Its Patent and Competition Risks ↗

March 07, 2026

Via The Motley Fool

Forget Amarin: This Oft-Overlooked Pharma Powerhouse Is a Better Buy Now ↗

March 03, 2026

Via The Motley Fool

Effects of Icosapent Ethyl on Risk and Duration of Hospitalizations and Death in REDUCE-IT® Post Hoc Analysis Published in the European Journal of Preventive Cardiology

March 02, 2026

From Amarin Corporation plc

Via GlobeNewswire

Amarin (AMRN) Q4 2025 Earnings Call Transcript ↗

February 25, 2026

Via The Motley Fool

Amarin Reports Fourth Quarter and Full Year 2025 Financial Results

February 25, 2026

From Amarin Corporation plc

Via GlobeNewswire

This American Heart Month Amarin Spotlights the Need to Prioritize Proven Widely Available Yet Underutilized Therapies in the Battle Against Cardiovascular Disease

February 23, 2026

From Amarin Corporation plc

Via GlobeNewswire

Amarin to Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on February 25, 2026

February 11, 2026

From Amarin Corporation plc

Via GlobeNewswire

Amarin Applauds Breakthroughs In Therapies For Patients With Elevated Triglycerides; Company’s VASCEPA®/VAZKEPA® (Icosapent Ethyl) Franchise Well Positioned To Benefit Globally From Broadened Category Commercialization

January 09, 2026

From Amarin Corporation plc

Via GlobeNewswire

Amarin Announces Preliminary 2025 Financial Highlights and Operational Accomplishments, Including Achieving Positive Cash Flow; Company Well Positioned to Capture Global Growth Opportunities

January 08, 2026

From Amarin Corporation plc

Via GlobeNewswire

New REDUCE-IT® Aspirin Analysis Presented at AHA Scientific Sessions 2025 Reinforces VASCEPA®/VAZKEPA® (Icosapent Ethyl) Reduced Cardiovascular Events in High-Risk Patients

November 09, 2025

From Amarin Corporation plc

Via GlobeNewswire

Amarin To Present New Analyses Affirming Robustness of Data from REDUCE-IT and Additional Mechanisms of Action of Eicosapentaenoic Acid (EPA) at American Heart Association (AHA) Scientific Sessions 2025

November 03, 2025

From Amarin Corporation plc

Via GlobeNewswire

Amarin Corp (NASDAQ:AMRN) Beats Q3 2025 Earnings and Revenue Estimates ↗

October 29, 2025

Via Chartmill

Amarin Reports Third Quarter 2025 Financial Results

October 29, 2025

From Amarin Corporation plc

Via GlobeNewswire

Frequently Asked Questions

Is Amarin Corporation plc - American Depositary Shares publicly traded?

Yes, Amarin Corporation plc - American Depositary Shares is publicly traded.

What exchange does Amarin Corporation plc - American Depositary Shares trade on?

Amarin Corporation plc - American Depositary Shares trades on the Nasdaq Stock Market

What is the ticker symbol for Amarin Corporation plc - American Depositary Shares?

The ticker symbol for Amarin Corporation plc - American Depositary Shares is AMRN on the Nasdaq Stock Market

What is the current price of Amarin Corporation plc - American Depositary Shares?

The current price of Amarin Corporation plc - American Depositary Shares is 14.22

When was Amarin Corporation plc - American Depositary Shares last traded?

The last trade of Amarin Corporation plc - American Depositary Shares was at 06/03/26 02:53 PM ET

What is the market capitalization of Amarin Corporation plc - American Depositary Shares?

The market capitalization of Amarin Corporation plc - American Depositary Shares is 5.79B

How many shares of Amarin Corporation plc - American Depositary Shares are outstanding?

Amarin Corporation plc - American Depositary Shares has 6B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.